3m_istock-458291485_wellesenterprises

wellesenterprises / iStockphoto.com

21 June 2017Americas

BIO 2017: Section 101 raises fundamental policy question, says 3M

The perceived problem with 35 USC section 101 is a “fundamental question of national innovation policy”, claimed Kevin Rhodes, vice president and chief IP counsel at multinational conglomerate 3M.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Lanham Act: brand owners’ current weapon of choice

11 June 2020 As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

BIO 2018: Stop bashing the patent system, says USPTO director

5 June 2018 “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More on this story

Lanham Act: brand owners’ current weapon of choice

11 June 2020 As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

BIO 2018: Stop bashing the patent system, says USPTO director

5 June 2018 “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More on this story

Lanham Act: brand owners’ current weapon of choice

11 June 2020 As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

BIO 2018: Stop bashing the patent system, says USPTO director

5 June 2018 “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages